Key Dates

None

National Cancer Institute (NCI)

The National Cancer Institute (NCI) intends to issue a U10 NCI National Clinical Trials Network (NCTN) – Network Group Statistics and Data Management Center notice of funding opportunity (NOFO). The NCTN Network Group Statistics and Data Management Centers will provide statistical expertise for effective scientific design, conduct, and data management of clinical trials led by the associated NCTN Network Group Operations Center as well as for translational and other ancillary studies associated with the trials. The primary goal of the NCTN is the conduct of multi-center, late-phase, clinical treatment trials (i.e., randomized phase 2 and phase 3 trials) and advanced imaging trials across a broad range of cancers, modalities, and diverse patient populations as part of the NCI's overall clinical research program for adults, adolescents and young adults, and children with cancer. The NCTN also conducts, as necessary, preliminary studies needed for development of definitive trials, especially umbrella/basket trials and rare tumor trials, when an extensive, national patient catchment area is required.

This Notice of Intent to Publish is being provided to allow sufficient time for applicants to develop strong applications.
The NOFO is expected to be published in Fall 2024 with only one expected application due date in late February 2025.
 

This Notice encourages investigators with expertise and experience related to the design, statistical analysis, and data management of cancer treatment clinical trials, especially late-phase randomized phase 2 and phase 3 trials to begin to consider applying for this NOFO. In addition, the investigators should also have expertise in trial monitoring to ensure appropriate trial conduct and outcomes validation and in data management processes and procedures for all phases of clinical trials to ensure serious adverse event reporting, timely trial completion, compliance, and data validity. The investigators statistical expertise should also extend to the appropriate design and analyses for translational and other ancillary studies that may be associated with the trials.  The funding provides support as well for participation in the collective management of the NCTN Program and facilitation of collaborations with other NCTN Groups, NCI-sponsored programs, and clinical trials organizations.

Funding Information

Applications are not being solicited at this time. 

Inquiries

Please direct all inquiries to:

Margaret Mooney, M.D.
National Cancer Institute (NCI)
Telephone: 240-276-6006
Email: [email protected]